Team - Enosi Life Sciences (2022)

Joining Forces For Progress

Inspired by the Greek word enosis, or “union,” Enosi Life Sciences was born when world-renowned scientists Professor Sir Marc Feldmann and Dr. H. Michael Shepard joined forces to focus on second generation therapeutics for cancer and autoimmune diseases based on their previous successes.

Team - Enosi Life Sciences (1)

H. Michael Shepard, Ph.D

President, Co-Founder & CSO

Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics. He is best known for his invention of "Herceptin"/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD). Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field—working at Genentech (sold to Roche - $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.

Team - Enosi Life Sciences (2)

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-Founder

Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford. With Sir Ravinder Maini, he identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.Remicade sales amount to more than $50B USD globally. Professor Sir Marc Feldmann is a Fellow of the Royal Society of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent. He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, and the Ernst Schering Award.

(Video) Let's Talk Crypto - Bill Barden of Enosi

Team - Enosi Life Sciences (3)

James N. Woody

Executive Chairman

James N. Woody Bio

  • Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
  • In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.
  • He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA.
  • Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim's team developed the blockbuster drug Remicade.
  • Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program.
  • He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service.
  • Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children's Hospital (Stanford).
  • Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children's Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.

Read Bio

Team - Enosi Life Sciences (4)

Jeff Huitt

CFO

(Video) Cancer Research- MoneyTV with Donald Baillargeon

Jeff Huitt Bio

  • Jeff has more than 20 years' experience driving the financial function at start-up and public companies.
  • His experience includes Orion Consulting, where he spent the last nine years as Principal and Consultant providing financial operations and funding support for start-up companies. Prior to Orion Consulting, Huitt acted as CFO at XsunX, Inc., Parking Stripes Advertising, Diamondback Tactical, iSherpa Capital and AirCover Network Solutions.
  • He holds an MBA in Management from the University of Denver and is a Certified Public Accountant (CPA) in Colorado.

Read Bio

Team - Enosi Life Sciences (5)

Dr. Patrick William Gray

CEO

Dr. Patrick William Gray Bio

  • Dr. Gray comes to Enosi with more than 40 years of experience in the biotech, biochemistry, and molecular biology sectors. During his time in the field, he's developed over 40 U.S. patents for more than 20 different technologies. His experience and dedication to developing new ways to improve people's health made him the perfect candidate to advance Enosi's next generation of autoimmune, cancer and acute inflammation therapies that induce disease regression, and prevent relapse while dramatically reducing patient side effects.
  • Dr. Gray's long list of accomplishments includes the first cloning and characterization of the Hepatitis B viral surface antigen. This work led to the development of the HBV vaccine that saves approximately two million lives a year. Dr. Gray's dedication to drug discovery and saving lives will help provide leadership, direction, and vision to Enosi's rapidly growing organization.
  • Before being named Enosi Life Sciences CEO, Dr. Gray served as CEO for Pascal Biosciences (2015-2021) and was CEO of Nura, Inc. (2003-2006). Dr. Gray has had close relationships with Enosi founders, since he began his career in biotechnology in 1980 at Genentech as a coworker of Dr. Shepard, and he was a scientist in Dr. Feldmann's lab from 1989-1990. Dr. Gray has also received awards and honors throughout his career including a Distinguished Alumni Fellows Award from his alma mater, theUniversity of Oregon. He holds a Ph.D. in Chemistry from theUniversity of Colorado, Boulder, CO.

Read Bio

(Video) Cloud Infrastructure as .NET code using Pulumi by James Murphy

A Conversation With Enosi's Founders

Co-Founders Professor Sir Marc Feldmann and Dr. Mike Shepard discuss the genesis of the idea for founding Enosi Life Sciences and what they hope to accomplish with forthcoming research and treatment developments. Executive Chairman Dr. James N. Woody moderates.

Team - Enosi Life Sciences (6)

James N. Woody

Executive Chairman

  • Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
  • In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.
  • He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA.
  • Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim’s team developed the blockbuster drug Remicade.
  • Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program.
  • He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service.
  • Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children’s Hospital (Stanford).
  • Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.
(Video) Η σύγκρουση με τον γαλαξία της Ανδρομέδας | Astronio X (#2)
Team - Enosi Life Sciences (7)

H. Michael Shepard, Ph.D.

CEO & Co-founder

  • Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
  • Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
  • Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
  • Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.
Team - Enosi Life Sciences (8)

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-founder

  • Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
  • With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
  • Anti-TNF sales > $50B USD globally.
  • Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
  • He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.

Videos

1. 2020 Laureate Lecture- BS- Translating Molecular Insights in Autoimmunity into Effective Therapy
(TangPrize)
2. May Institute 2020 Online - Nuno Bandeira and Meena Choi: Introduction to MassIVE.quant
(May Institute NEU)
3. Super September Session 2021 29th September 2021
(Phillips Coaching)
4. AMPC Industry Forum Webinar: Enosi Clean Energy
(Australian Meat Processor Corporation)
5. Here Be Dragons
(inFact with Brian Dunning)
6. Orange Hydrogen-The Golden Zero-Carbon Energy DIRECT from Uneconomic Oil & Gas Reservoirs
(BUOG SPE Student Chapter)

Top Articles

You might also like

Latest Posts

Article information

Author: Golda Nolan II

Last Updated: 10/20/2022

Views: 6498

Rating: 4.8 / 5 (58 voted)

Reviews: 81% of readers found this page helpful

Author information

Name: Golda Nolan II

Birthday: 1998-05-14

Address: Suite 369 9754 Roberts Pines, West Benitaburgh, NM 69180-7958

Phone: +522993866487

Job: Sales Executive

Hobby: Worldbuilding, Shopping, Quilting, Cooking, Homebrewing, Leather crafting, Pet

Introduction: My name is Golda Nolan II, I am a thoughtful, clever, cute, jolly, brave, powerful, splendid person who loves writing and wants to share my knowledge and understanding with you.